髓母细胞瘤组织MEF2C表达与预后相关性分析  

Expression of MEF2C in medulloblastoma and its relationship with patients' prognosis

作　　者：左丽[1] 李静文[1] 孙立[1] 刘广丽[1] 刘兴田[1] 

机构地区：[1]泰安市中心医院检验科,山东泰安271000

出　　处：《中华肿瘤防治杂志》2014年第3期207-210,共4页Chinese Journal of Cancer Prevention and Treatment

基　　金：山东省自然科学基金(ZR2009CM132);泰安市科技发展引导计划(20103043)

摘　　要：目的:探讨肌细胞增强因子2C(myocyte enhancer factor 2C,MEF2C)表达情况与髓母细胞瘤患者预后的关系。方法:选取3家三级甲等医院2001-01-01-2007-12-31病理确诊的髓母细胞瘤患者56例,其中泰安市中心医院12例,齐鲁医院26例,山东省立医院18例;对照组脑组织取自泰安市中心医院2010-01-01-2010-12-31 12例非肿瘤脑外伤患者。免疫组织化学法检测56例髓母细胞瘤患者肿瘤组织和12例非肿瘤患者脑组织中MEF2C的表达;收集髓母细胞瘤患者临床资料,应用统计学方法对髓母细胞瘤患者进行生存分析。结果:髓母细胞瘤患者肿瘤组织MEF2C相对高表达率为53.6%(30/56),非肿瘤患者脑组织MEF2C相对高表达率为0(0/12),两组比较差异有统计学意义,χ2=11.50,P=0.001;肿瘤患者肿瘤组织MEF2C相对高表达组与相对低表达组间生存时间的差异有统计学意义,χ2=4.34,P=0.037。MEF2C相对高表达(P=0.023)、肿瘤转移(P=0.042)与患者3年生存率降低显著有关,而患者性别、年龄、肿瘤大小、肿瘤部位与患者3年生存率无关,P值均>0.05。结论:MEF2C在患者肿瘤组织中的高表达可降低患者3年生存率,是患者预后不良的危险因素之一。OBJECTIVE： To investigate the relationship between expression of the myocyte enhancer factor 2C （MEF2C） and prognosis of medulloblastoma patients. METHODS： MEF2C expression levels were detected in tumor tis sues of 56 patients with medulloblastoma from January 1st,2001 to December 31st,2007 and 12 patients with non-tumor by immunohistoehemistry method from January 1st, 2010 to December 31st, 2010. The clinical data of medulloblastoma pa- tients were collected and the life survival of patients were analyzed stastistically. RESULTS： The rate of expression level of MEF2C in medullohlastoma tissues was 53.6% （30/56） which was significantly higher than that of the non-tumor patients brain tissue（0,0/12,χ2= 11.50,P=0. 001）. The survival analysis showed that the survival rate of patients with relatively high expression of MEF2C was significantly lower than the one of patients with relatively low expression of MEF2C （χ2= 4.34 ,P=0. 037）. Relatively high expression of MEF2C（P=0. 023） and tumor metastasis（P=-0. 042） were significantly related to the decreas of g-year survival rate of patients, but not related to the patient＇s gender, age, tumor size, tumor sites and tumor staging （all P2〉0.05）. CONCLUSION： High expression level of MEF2C in tumor tissue of MB patients can de crease 3-year survival rate and is one of risk factors which are related to poor prognosis.

关 键 词：肌细胞增强因子2C 髓母细胞瘤 转移 预后 

分 类 号：R739.4[医药卫生—肿瘤]